ATE498693T1 - Marker zur prognose der reaktion auf therapie bzw. der überlebensrate von brustkrebspatienten - Google Patents
Marker zur prognose der reaktion auf therapie bzw. der überlebensrate von brustkrebspatientenInfo
- Publication number
- ATE498693T1 ATE498693T1 AT04029486T AT04029486T ATE498693T1 AT E498693 T1 ATE498693 T1 AT E498693T1 AT 04029486 T AT04029486 T AT 04029486T AT 04029486 T AT04029486 T AT 04029486T AT E498693 T1 ATE498693 T1 AT E498693T1
- Authority
- AT
- Austria
- Prior art keywords
- predicting
- response
- markers
- therapy
- breast cancer
- Prior art date
Links
- 230000004083 survival effect Effects 0.000 title abstract 2
- 206010006187 Breast cancer Diseases 0.000 title 1
- 208000026310 Breast neoplasm Diseases 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 230000030933 DNA methylation on cytosine Effects 0.000 abstract 1
- 108091034117 Oligonucleotide Proteins 0.000 abstract 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 abstract 1
- 210000000481 breast Anatomy 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 230000002124 endocrine Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/154—Methylation markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/16—Primer sets for multiplex assays
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Wood Science & Technology (AREA)
- Pathology (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP03090432 | 2003-12-11 | ||
| EP04090041 | 2004-02-10 | ||
| EP04090127 | 2004-04-01 | ||
| EP04013328 | 2004-06-05 | ||
| EP04090380 | 2004-09-30 | ||
| EP04027213 | 2004-11-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE498693T1 true ATE498693T1 (de) | 2011-03-15 |
Family
ID=34637445
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04029486T ATE498693T1 (de) | 2003-12-11 | 2004-12-13 | Marker zur prognose der reaktion auf therapie bzw. der überlebensrate von brustkrebspatienten |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US9017944B2 (de) |
| EP (1) | EP1692316A2 (de) |
| JP (2) | JP2007513621A (de) |
| AT (1) | ATE498693T1 (de) |
| AU (3) | AU2004237861B2 (de) |
| CA (2) | CA2549852A1 (de) |
| DE (1) | DE602004031405D1 (de) |
| WO (1) | WO2005059172A2 (de) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6331393B1 (en) | 1999-05-14 | 2001-12-18 | University Of Southern California | Process for high-throughput DNA methylation analysis |
| EP1554407B1 (de) * | 2002-10-01 | 2009-07-29 | Epigenomics AG | Verfahren für die behandlung von proliferativen erkrankungen von brustzellen |
| JP2007513621A (ja) * | 2003-12-11 | 2007-05-31 | エピゲノミクス アーゲー | 乳房細胞増殖性障害の改良された処置のための方法および核酸 |
| EP1961827A3 (de) * | 2004-07-18 | 2008-09-17 | Epigenomics AG | Epigenetische Verfahren und Nukleinsäuren für den Nachweis von proliferativen Erkrankungen von Mammazellen |
| ES2534139T3 (es) | 2004-12-02 | 2015-04-17 | Epigenomics Ag | Métodos y ácidos nucleicos para el análisis de la expresión génica asociada con el pronóstico de trastornos proliferativos de células de próstata |
| KR101708544B1 (ko) | 2005-04-15 | 2017-02-20 | 에피제노믹스 아게 | 세포 증식 질환을 분석하기 위한 방법 및 핵산 |
| WO2006131391A1 (en) * | 2005-06-10 | 2006-12-14 | Epigenomics Ag | Prognostic assay for prediction of treatment response and/or survival of breast cell proliferative disorder patients |
| WO2007003397A2 (en) * | 2005-07-01 | 2007-01-11 | Epigenomics Ag | Method and nucleic acids for the improved treatment of cancers |
| WO2007047699A1 (en) * | 2005-10-17 | 2007-04-26 | Epigenomics Ag | Method and nucleic acids for the improved treatment of breast cancers |
| WO2007085497A2 (en) * | 2006-01-30 | 2007-08-02 | Epigenomics Ag | Markers for the prediction of outcome of anthracycline treatment |
| US8068994B2 (en) * | 2007-07-27 | 2011-11-29 | Wayne State University | Method for analyzing biological networks |
| EP2193209B1 (de) * | 2007-09-17 | 2014-11-12 | Koninklijke Philips N.V. | Verfahren zur analyse von brustkrebserkrankungen |
| BRPI0818780A2 (pt) * | 2007-10-19 | 2015-04-22 | Genentech Inc | Anticorpo anti-tenb2 planejados por cisteína e conjugados de medicamento com anticorpos |
| EP3048176B1 (de) * | 2009-04-20 | 2019-03-06 | Erasmus University Medical Center Rotterdam | Verfahren zur diagnose von blasenkrebs |
| US20120190024A1 (en) * | 2009-06-30 | 2012-07-26 | Sysmex Corporation | Method for determining presence or absence of epithelial cancer-origin cell in biological sample, and molecular marker and kit therefor |
| US20110282043A1 (en) * | 2010-03-12 | 2011-11-17 | Cenetron Diagnostics Llc | Methods and compositions comprising nucleic acid polymerization enhancers |
| EP2505665A1 (de) * | 2011-03-31 | 2012-10-03 | Queen Mary And Westfield College, University Of London | Krebsmarker |
| JP2014519319A (ja) * | 2011-05-12 | 2014-08-14 | ザ・ジョンズ・ホプキンス・ユニバーシティー | エピジェネティックドメインの安定性の全般的な損失を通して癌を検出する方法およびその組成物 |
| NO2729579T3 (de) | 2011-07-08 | 2018-03-03 | ||
| US10316361B2 (en) | 2011-07-15 | 2019-06-11 | The John Hopkins University | Genome-wide methylation analysis and use to identify genes specific to breast cancer hormone receptor status and risk of recurrence |
| GB201204785D0 (en) * | 2012-03-19 | 2012-05-02 | Queen Mary & Westfield College | Method for determining prognosis of prostate cancer in a subject |
| EP2971179B1 (de) | 2013-03-14 | 2019-01-09 | Mayo Foundation for Medical Education and Research | Neoplasma-erkennung |
| WO2016160454A1 (en) | 2015-03-27 | 2016-10-06 | Exact Sciences Corporation | Detecting esophageal disorders |
| US20170211035A1 (en) | 2016-01-25 | 2017-07-27 | American Sterilizer Company | Biological indicators |
| EP3421609B1 (de) * | 2016-02-24 | 2022-03-02 | FUJIFILM Corporation | Verfahren zur quantifizierung der chromosomenzahl |
| EP4528275A3 (de) | 2016-08-10 | 2025-05-14 | Grail, Inc. | Verfahren zur herstellung von dual-indexierten dna-bibliotheken für bisulfitumwandlungssequenzierung |
| WO2019012544A1 (en) * | 2017-07-13 | 2019-01-17 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | STRATEGY FOR DOUBLE PROBE DROPLETS FOR SPECIFIC DETECTION OF CIRCULATING DNA MOLECULES SPECIFIC TO A TISSUE |
| WO2019190908A1 (en) * | 2018-03-26 | 2019-10-03 | Rush University Medical Center | Method of treatment utilizing a gene expression signature predicting the response of her2-directed therapies |
| US12544472B2 (en) | 2018-12-27 | 2026-02-10 | Solventum Intellectual Properties Company | Multilayer test pack for sterilization monitoring |
| AU2020254760B2 (en) * | 2019-04-03 | 2025-10-23 | Exact Sciences Corporation | Detecting pancreatic ductal adenocarcinoma in plasma |
| WO2020252721A1 (en) * | 2019-06-20 | 2020-12-24 | The Johns Hopkins University | Dna methylation markers and their use in differentiation of suspected cancerous lymph node biopsy samples |
| KR102923870B1 (ko) | 2019-09-02 | 2026-02-06 | 주식회사 시선바이오머티리얼스 | 신규한 pna 올리고머, 이의 dna 메틸화 검출용도 및 이를 이용한 dna 메틸화 검출방법 |
| CN115910365B (zh) * | 2022-11-16 | 2024-02-13 | 华中科技大学同济医学院附属同济医院 | Eos-CRSwNP术前难治性评估模型的构建方法及预测系统 |
| WO2024258948A1 (en) * | 2023-06-12 | 2024-12-19 | Tru Diagnostics, Inc. | Method for predicting health of a human subject |
| CN117070633A (zh) * | 2023-10-05 | 2023-11-17 | 上海奕谱生物科技有限公司 | DNA甲基化标志物TAGMe-4及其在肿瘤检测中的用途 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5585481A (en) | 1987-09-21 | 1996-12-17 | Gen-Probe Incorporated | Linking reagents for nucleotide probes |
| US5457183A (en) | 1989-03-06 | 1995-10-10 | Board Of Regents, The University Of Texas System | Hydroxylated texaphyrins |
| US5744101A (en) | 1989-06-07 | 1998-04-28 | Affymax Technologies N.V. | Photolabile nucleoside protecting groups |
| US5574142A (en) | 1992-12-15 | 1996-11-12 | Microprobe Corporation | Peptide linkers for improved oligonucleotide delivery |
| SE501439C2 (sv) | 1993-06-22 | 1995-02-13 | Pharmacia Lkb Biotech | Sätt och anordning för analys av polynukleotidsekvenser |
| US5837832A (en) | 1993-06-25 | 1998-11-17 | Affymetrix, Inc. | Arrays of nucleic acid probes on biological chips |
| DE69417918T2 (de) | 1993-11-30 | 2000-01-05 | Mcgill University, Montreal | Dna methyltransferase inhibierung |
| US5597696A (en) | 1994-07-18 | 1997-01-28 | Becton Dickinson And Company | Covalent cyanine dye oligonucleotide conjugates |
| US5871917A (en) | 1996-05-31 | 1999-02-16 | North Shore University Hospital Research Corp. | Identification of differentially methylated and mutated nucleic acids |
| US6017704A (en) | 1996-06-03 | 2000-01-25 | The Johns Hopkins University School Of Medicine | Method of detection of methylated nucleic acid using agents which modify unmethylated cytosine and distinguishing modified methylated and non-methylated nucleic acids |
| US5786146A (en) | 1996-06-03 | 1998-07-28 | The Johns Hopkins University School Of Medicine | Method of detection of methylated nucleic acid using agents which modify unmethylated cytosine and distinguishing modified methylated and non-methylated nucleic acids |
| DE19754482A1 (de) | 1997-11-27 | 1999-07-01 | Epigenomics Gmbh | Verfahren zur Herstellung komplexer DNA-Methylierungs-Fingerabdrücke |
| US5958773A (en) | 1998-12-17 | 1999-09-28 | Isis Pharmaceuticals Inc. | Antisense modulation of AKT-1 expression |
| US6331393B1 (en) | 1999-05-14 | 2001-12-18 | University Of Southern California | Process for high-throughput DNA methylation analysis |
| US6596488B2 (en) | 2000-03-30 | 2003-07-22 | City Of Hope | Tumor suppressor gene |
| AUPR142500A0 (en) * | 2000-11-13 | 2000-12-07 | Human Genetic Signatures Pty Ltd | A peptide nucleic acid-based assay for the detection of specific nucleic acid sequences |
| US6756200B2 (en) * | 2001-01-26 | 2004-06-29 | The Johns Hopkins University School Of Medicine | Aberrantly methylated genes as markers of breast malignancy |
| US7473767B2 (en) | 2001-07-03 | 2009-01-06 | The Institute For Systems Biology | Methods for detection and quantification of analytes in complex mixtures |
| DE10228917A1 (de) | 2002-06-24 | 2004-01-22 | Epigenomics Ag | Vorrichtung zur Handhabung von Flüssigkeiten in einer Mehrzahl von Kanälen |
| EP1554407B1 (de) | 2002-10-01 | 2009-07-29 | Epigenomics AG | Verfahren für die behandlung von proliferativen erkrankungen von brustzellen |
| JP2007513621A (ja) * | 2003-12-11 | 2007-05-31 | エピゲノミクス アーゲー | 乳房細胞増殖性障害の改良された処置のための方法および核酸 |
| WO2006113671A2 (en) * | 2005-04-15 | 2006-10-26 | Oncomethylome Sciences, S.A. | Methylation markers for diagnosis and treatment of cancers |
-
2004
- 2004-12-13 JP JP2006543511A patent/JP2007513621A/ja active Pending
- 2004-12-13 CA CA002549852A patent/CA2549852A1/en not_active Abandoned
- 2004-12-13 US US10/582,705 patent/US9017944B2/en active Active
- 2004-12-13 DE DE200460031405 patent/DE602004031405D1/de not_active Expired - Lifetime
- 2004-12-13 JP JP2004360619A patent/JP2005204651A/ja not_active Withdrawn
- 2004-12-13 EP EP04820431A patent/EP1692316A2/de not_active Withdrawn
- 2004-12-13 WO PCT/EP2004/014170 patent/WO2005059172A2/en not_active Ceased
- 2004-12-13 AU AU2004237861A patent/AU2004237861B2/en not_active Ceased
- 2004-12-13 AT AT04029486T patent/ATE498693T1/de not_active IP Right Cessation
- 2004-12-13 AU AU2004298537A patent/AU2004298537A1/en not_active Abandoned
- 2004-12-13 CA CA 2487578 patent/CA2487578A1/en not_active Abandoned
-
2010
- 2010-03-16 AU AU2010201017A patent/AU2010201017A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2007513621A (ja) | 2007-05-31 |
| WO2005059172A3 (en) | 2005-12-08 |
| US9017944B2 (en) | 2015-04-28 |
| AU2010201017A1 (en) | 2010-04-08 |
| CA2549852A1 (en) | 2005-06-30 |
| US20080254447A1 (en) | 2008-10-16 |
| WO2005059172A2 (en) | 2005-06-30 |
| EP1692316A2 (de) | 2006-08-23 |
| AU2004237861A1 (en) | 2005-06-30 |
| CA2487578A1 (en) | 2005-06-11 |
| DE602004031405D1 (de) | 2011-03-31 |
| AU2004237861B2 (en) | 2010-04-29 |
| JP2005204651A (ja) | 2005-08-04 |
| AU2004298537A1 (en) | 2005-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE602004031405D1 (de) | Marker zur Prognose der Reaktion auf Therapie bzw. der Überlebensrate von Brustkrebspatienten | |
| ATE437962T1 (de) | Verfahren für die behandlung von proliferativen erkrankungen von brustzellen | |
| MX2009012722A (es) | Variantes geneticas sobre chr 5p12 y 10q26 como marcadores para el uso en la evaluacion del riesgo, diagnostico, pronostico y tratamiento del cancer de mama. | |
| NZ577805A (en) | Genetic markers for risk management of cardiac arrhythmia | |
| WO2007140958A3 (en) | Method for identifying whether a patient will be responder or not to immunotherapy | |
| NZ587903A (en) | Susceptibility for lung cancer using the polymorphic marker rs1051730 | |
| WO2006133420A3 (en) | Treatment of patients with cancer therapy | |
| WO2005116259A3 (en) | Use of gene expression profiling to predict survival in cancer patient | |
| NO20081884L (no) | Modulasjon av glukagonreseptorekspresjon | |
| AU2003293141A8 (en) | Methods for identifying risk of breast cancer and treatments thereof | |
| WO2004078035A3 (en) | Expression profiles for breast cancer and methods of use | |
| Griner et al. | Aggressive myeloid leukemia formation is directed by the Musashi 2/Numb pathway | |
| WO2006133361A3 (en) | Use of gene expression profiling to predict survival in cancer patient | |
| AR049564A1 (es) | Metodos para la evaluacion y tratamiento del cancer | |
| GB0228337D0 (en) | Replication protein | |
| JP2014525270A5 (de) | ||
| DE602004032329D1 (de) | Marker für präkanzeröse und kanzeröse zellen sowie verfahren zur störung der zellproliferation darin | |
| PL1618195T3 (pl) | Sposób selektywnego hamowania ludzkiego genu N-myc w nowotworach z ekspresją N-myc przez antysensowne i sensowne kwasy peptydonukleinowe | |
| WO2005039645A3 (en) | Sp1 and sp3 targeted cancer therapies and therapeutics | |
| CN108642176B (zh) | Part1作为乳腺癌诊断、治疗以及预后标志物的应用 | |
| GB0320648D0 (en) | Molecular marker | |
| DE50015171D1 (de) | Rna polymerase i transkriptionsfaktor tif-ia | |
| WO2005117974A3 (en) | Cancer treatment method by inhibiting mage gene expression or function | |
| Isozaki et al. | Acquired resistance to a new ALK inhibitor, alectinib in lung cancer | |
| ATE557089T1 (de) | Oligonukleotide zur hemmung und zum nachweis von humanen argonaute-proteinen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |